New Developments in Secondary Stroke Prevention: Impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on Clinical Management

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Secondary stroke prevention is an important goal of poststroke patient treatment. Various pharmacologic approaches have been advocated, but the relative efficacy and safety of these regimens has remained the subject of much debate. Recently released data from the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) indicated that combination therapy with aspirin and extended-release dipyridamole was more effective than aspirin monotherapy, and probably more effective than anticoagulants, for the prevention of cerebrovascular events after a stroke or transient ischemic attack. When viewed in light of results of earlier trials, these findings confirmed that combination aspirin plus extended-release dipyridamole therapy improved outcomes in these patients and is a recommended option for poststroke patient treatment.

Original languageEnglish (US)
Pages (from-to)263-267
Number of pages5
JournalJournal of Stroke and Cerebrovascular Diseases
Volume16
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Secondary Prevention
Ischemia
Stroke
Clinical Trials
Transient Ischemic Attack
Therapeutics
Anticoagulants
Aspirin
Safety
Dipyridamole Drug Combination Aspirin

Keywords

  • Antiplatelets
  • aspirin
  • dipyridamole
  • secondary stroke prevention
  • stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Health Professions(all)

Cite this

@article{46b01f2c827443e189a47d2a96024678,
title = "New Developments in Secondary Stroke Prevention: Impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on Clinical Management",
abstract = "Secondary stroke prevention is an important goal of poststroke patient treatment. Various pharmacologic approaches have been advocated, but the relative efficacy and safety of these regimens has remained the subject of much debate. Recently released data from the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) indicated that combination therapy with aspirin and extended-release dipyridamole was more effective than aspirin monotherapy, and probably more effective than anticoagulants, for the prevention of cerebrovascular events after a stroke or transient ischemic attack. When viewed in light of results of earlier trials, these findings confirmed that combination aspirin plus extended-release dipyridamole therapy improved outcomes in these patients and is a recommended option for poststroke patient treatment.",
keywords = "Antiplatelets, aspirin, dipyridamole, secondary stroke prevention, stroke",
author = "Helmi Lutsep",
year = "2007",
month = "11",
doi = "10.1016/j.jstrokecerebrovasdis.2007.07.005",
language = "English (US)",
volume = "16",
pages = "263--267",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - New Developments in Secondary Stroke Prevention

T2 - Impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on Clinical Management

AU - Lutsep, Helmi

PY - 2007/11

Y1 - 2007/11

N2 - Secondary stroke prevention is an important goal of poststroke patient treatment. Various pharmacologic approaches have been advocated, but the relative efficacy and safety of these regimens has remained the subject of much debate. Recently released data from the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) indicated that combination therapy with aspirin and extended-release dipyridamole was more effective than aspirin monotherapy, and probably more effective than anticoagulants, for the prevention of cerebrovascular events after a stroke or transient ischemic attack. When viewed in light of results of earlier trials, these findings confirmed that combination aspirin plus extended-release dipyridamole therapy improved outcomes in these patients and is a recommended option for poststroke patient treatment.

AB - Secondary stroke prevention is an important goal of poststroke patient treatment. Various pharmacologic approaches have been advocated, but the relative efficacy and safety of these regimens has remained the subject of much debate. Recently released data from the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) indicated that combination therapy with aspirin and extended-release dipyridamole was more effective than aspirin monotherapy, and probably more effective than anticoagulants, for the prevention of cerebrovascular events after a stroke or transient ischemic attack. When viewed in light of results of earlier trials, these findings confirmed that combination aspirin plus extended-release dipyridamole therapy improved outcomes in these patients and is a recommended option for poststroke patient treatment.

KW - Antiplatelets

KW - aspirin

KW - dipyridamole

KW - secondary stroke prevention

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=36148958196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148958196&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2007.07.005

DO - 10.1016/j.jstrokecerebrovasdis.2007.07.005

M3 - Article

C2 - 18035244

AN - SCOPUS:36148958196

VL - 16

SP - 263

EP - 267

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 6

ER -